[Treatment with inorganic iodine for Graves' hyperthyroidism].
Nowadays, patients with Graves' hyperthyroidism are initially treated with methimazole or propylthiouracil. Several serious adverse reactions like agranulocytosis are caused by these drugs. Inorganic iodine decreases serum thyroid hormone concentrations in patients with Graves' hyperthyroidism without adverse reaction, but this effect usually continues only a limited time. However, a virtually complete remission or longstanding euthyroid state may be obtained with inorganic iodine therapy alone in patients with mild Graves' disease, who show small thyroid volume and low TRAb titers. Inorganic iodine therapy may become one of the treatment methods in the patients with mild Graves' hyperthyroidism.
Noh
Jaeduk Yoshimura
JY
Ito Hospital.
Chino
Toshiko
T
Ito
Koichi
K
D000818:Animals; D013956:Antithyroid Agents / Q000009:adverse effects; D001323:Autoantibodies / Q000097:blood; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating; D007454:Iodides / Q000008:administration & dosage* / Q000378:metabolism; D011247:Pregnancy; D012074:Remission Induction; D012720:Severity of Illness Index; D027981:Symporters / Q000378:metabolism / Q000502:physiology; D013961:Thyroid Gland / Q000378:metabolism / Q000473:pathology; D000099209:Sodium-Iodide Symporters
D013956:Antithyroid Agents; D001323:Autoantibodies; D018828:Immunoglobulins, Thyroid-Stimulating; D007454:Iodides; D027981:Symporters; D000099209:Sodium-Iodide Symporters; C094372:thyrotropin-binding inhibitory immunoglobulin